These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 19726410)

  • 41. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.
    Schweitzer KJ; Brüssel T; Leitner P; Krüger R; Bauer P; Woitalla D; Tomiuk J; Gasser T; Berg D
    J Neurol; 2007 May; 254(5):613-6. PubMed ID: 17415511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
    Anfossi M; Colao R; Gallo M; Bernardi L; Conidi ME; Frangipane F; Vasso F; Puccio G; Clodomiro A; Mirabelli M; Curcio SA; Torchia G; Smirne N; Di Lorenzo R; Maletta R; Bruni AC
    J Alzheimers Dis; 2014; 38(2):351-7. PubMed ID: 23963289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.
    Azkona G; López de Maturana R; Del Rio P; Sousa A; Vazquez N; Zubiarrain A; Jimenez-Blasco D; Bolaños JP; Morales B; Auburger G; Arbelo JM; Sánchez-Pernaute R
    Mol Neurobiol; 2018 Jan; 55(1):506-516. PubMed ID: 27975167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical genetics of Parkinson's disease and related disorders.
    Wider C; Wszolek ZK
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S229-32. PubMed ID: 18267241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells.
    Ortiz-Ortiz MA; Morán JM; Ruiz-Mesa LM; Niso-Santano M; Bravo-SanPedro JM; Gómez-Sánchez R; González-Polo RA; Fuentes JM
    Neurosci Lett; 2010 Jan; 468(2):120-4. PubMed ID: 19879924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease.
    Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME
    Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.
    Marras C; Schüle B; Munhoz RP; Rogaeva E; Langston JW; Kasten M; Meaney C; Klein C; Wadia PM; Lim SY; Chuang RS; Zadikof C; Steeves T; Prakash KM; de Bie RM; Adeli G; Thomsen T; Johansen KK; Teive HA; Asante A; Reginold W; Lang AE
    Neurology; 2011 Jul; 77(4):325-33. PubMed ID: 21753163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parkinson's disease in a dish - Using stem cells as a molecular tool.
    Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R
    Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2.
    Dächsel JC; Mata IF; Ross OA; Taylor JP; Lincoln SJ; Hinkle KM; Huerta C; Ribacoba R; Blazquez M; Alvarez V; Farrer MJ
    Neurosci Lett; 2006 Dec; 410(2):80-4. PubMed ID: 17095157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parkinson's disease: from monogenic forms to genetic susceptibility factors.
    Lesage S; Brice A
    Hum Mol Genet; 2009 Apr; 18(R1):R48-59. PubMed ID: 19297401
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
    Nichols WC; Pankratz N; Hernandez D; Paisán-Ruíz C; Jain S; Halter CA; Michaels VE; Reed T; Rudolph A; Shults CW; Singleton A; Foroud T;
    Lancet; 2005 Jan 29-Feb 4; 365(9457):410-2. PubMed ID: 15680455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular pathogenesis of Parkinson disease: insights from genetic studies.
    Gasser T
    Expert Rev Mol Med; 2009 Jul; 11():e22. PubMed ID: 19631006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
    Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
    BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.